CLINICAL AND HEMATOLOGICAL RESPONSES TO HYDROXYUREA IN SICILIAN PATIENTS WITH Hb S/β-THALASSEMIA

Abstract

Although, several reports have detailed that hydroxyurea can ameliorate the clinical course of adult and pediatric patients with sickle cell anemia (Hb S or β^S), few clinical studies have been carried out in patients with β^S/β-thalassemia. In a two-year clinical study, we evaluated the efficacy of hydroxyurea in a group of 22 adult Sicilian patients with β^S/β-thalassemia with severe phenotypes. Among the 20 patients evaluated during 2 years of treatment, we observed a very good clinical response with a 93% reduction of the annual number of crises (median 7 versus 0.5 crises per year; P ≤ 0.001) and of days in hospital (mean 22±21.9 versus 1.2±2.3; P < 0.001), a significant increase in Hb F (7.5±5.3% versus 25.2±5.2%; P < 0.001) and in MCV (73.1±4.8 fL versus 96.4±7.2 fL; P < 0.001), and no significant modifications in Hb (9.6±1.3 g/dL versus 10.0±1.5 g/dL; P > 0.05) and in WBC (11.4±3.9 × 10⁹/L versus 10.2±3.9 × 10⁹/L; P > 0.05). Twelve patients had no crises from the first month of treatment; 16 patients showed a 2–3-fold increase over baseline in Hb F. During the study no severe complications and no important side effects of hydroxyurea were observed. Our data suggest that hydroxyurea efficacy in patients with β^S/β-thalassemial may be greater than that described in patients with sickle cell disease. This pattern and durability of response will need to be confirmed in a larger, randomized, clinical trial.